Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This study found that Hataedock may alleviate atopic dermatitis symptoms in mice by maintaining skin homeostasis and improving skin barrier formation through the endocannabinoid system.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.

This study presents a hypothesis that the EDAR V370A allele was positively selected in East Asian populations due to the stable aquatic resources in Late Pleistocene northern China, which may have offset the allele's metabolic costs and provided a selective advantage.

In this study, researchers propose that the EDAR V370A allele's positive selection in East Asian populations may be linked to stable aquatic resources from Late Pleistocene ecosystems in northern China, suggesting a "nutritional niche construction" framework where these resources offset the allele's metabolic costs.

This study suggests that compounds from turmeric and bitter have potential antiviral activity against the influenza A virus by inhibiting the polymerase PA-PB1, warranting further experimental verification.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This study indicates that MAGE-11 modulates androgen receptor transcriptional activity through F-box interactions, independent of the activation function 2 pathway, revealing a novel mechanism for androgen receptor regulation.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study found that 308 nm excimer lamp therapy provides a good clinical response with fewer adverse effects for limited alopecia areata but is less effective for widespread hair loss like alopecia totalis.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This study found that full-length Agouti protein modulates melanocortin receptor signaling through a dual mechanism involving competitive antagonism and receptor down-regulation, whereas the carboxyl-terminal fragment acts solely as a competitive antagonist.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This case report details a patient with myasthenia gravis and a malignant thymoma whose rising liver function tests, initially thought to be related to antibiotic use, were ultimately attributed to thymoma-associated multiorgan autoimmunity.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This study suggests that residues Val-889 and Arg-752 in the androgen receptor's steroid binding domain are crucial for NH2-/carboxyl-terminal interaction, affecting receptor stability and function.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

This study found that tofacitinib may inhibit CD8+ T cell infiltration in alopecia areata by affecting the linoleic acid metabolism-Mg2+ pathway in a sodium sulfide-induced mouse model, highlighting new insights for clinical diagnosis and treatment strategies.